Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDK2 | Q15119 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | HPGD | P15428 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.39 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.39 |
| ▸ | NAMPT | P43490 | 7/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 2/20 | 0.36 |
| ▸ | RAB9A | P51151 | 2/20 | 0.36 |
| ▸ | KLF5 | Q13887 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3273401 | 0.83 | PDK2 (0.41) | PDK2ALDH1A1KDM4EKMT2APOLB | |
| SCHEMBL3273686 | 0.80 | ALOX5 (0.41) | PDK2ALDH1A1HPGDGAARAB9A | |
| SCHEMBL8513311 | 0.74 | TRPA1 (0.35) | PDK2HPGDGAALMNAKMT2A | |
| SCHEMBL15510073 | 0.66 | BACE1 (0.46) | NAMPTKMT2APOLB | |
| SCHEMBL1520852 | 0.65 | HPGD (0.72) | ALDH1A1HPGDLMNAKMT2ANPC1 | |
| SCHEMBL29655544 | 0.64 | PTGER4 (0.46) | PDK2HPGDKDM4EL3MBTL1PTGS1 | |
| SCHEMBL13763531 | 0.63 | L3MBTL1 (0.80) | ALDH1A1HPGDKDM4EGAAL3MBTL1 | |
| SCHEMBL8826323 | 0.63 | ALDH1A1 (0.56) | ALDH1A1HPGDKDM4EGAAL3MBTL1 | |
| SCHEMBL6360257 | 0.63 | HDAC3 (0.72) | ALDH1A1HPGDKDM4EGAAL3MBTL1 | |
| SCHEMBL13128312 | 0.62 | PDK2 (1.00) | PDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8426447-B2 | Spiro-tricyclic ring compounds as beta-secretase modulators and methods of use | AMGEN INC. (US) | 2013-04-23 | — | — | US | disclosed |
| US-20100087429-A1 | SPIRO-TRICYCLIC RING COMPOUNDS AS BETA-SECRETASE MODULATORS AND METHODS OF USE | AMGEN INC. (US) | 2010-04-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100087429-A1 | SPIRO-TRICYCLIC RING COMPOUNDS AS BETA-SECRETASE MODULATORS AND METHODS OF USE | BACE1, BACE2, APP | PDK2 2740/4885ALDH1A1 392/4885HPGD 1347/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.